Pharmacologic treatment of cardiac arrhythmias: 25 years of progress.
This review of practical and theoretical advances in antiarrhythmic drug therapy consists of four parts. Part 1, on clinical applications, compares the approaches to treatment 25 years ago with those of today, examines the current status of antiarrhythmic drugs used 25 years ago, reports on drugs approved for clinical use during the past 25 years, reviews new experimental drugs and suggests an approach to classification of antiarrhythmic drugs. Part 2 summarizes the contributions of cellular electrophysiology to the understanding of drug action, with emphasis on the drug-induced block of the voltage- and time-dependent properties of the rapid sodium channel. The subsequent section contains a brief discussion of the impact made by the new knowledge and the new diagnostic technology on the contemporary practices. The main conclusions are 1) that the more rational approach to treatment has benefited proportionately more patients with supraventricular than with ventricular arrhythmias, and 2) that new advances have made it possible to design successful treatments for certain patients with problems that could not be resolved in the past.
D000200:Action Potentials / Q000187:drug effects; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D004562:Electrocardiography; D006321:Heart / Q000502:physiology; D006801:Humans; D008012:Lidocaine / Q000494:pharmacology / Q000627:therapeutic use; D010672:Phenytoin / Q000494:pharmacology; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D004071:Digitalis Glycosides; D010672:Phenytoin; D004077:Digoxin; D008012:Lidocaine; D011802:Quinidine; D011342:Procainamide